PL1599461T3 - Tiolaktony jako inhibitory NAALADazy - Google Patents
Tiolaktony jako inhibitory NAALADazyInfo
- Publication number
- PL1599461T3 PL1599461T3 PL04716834T PL04716834T PL1599461T3 PL 1599461 T3 PL1599461 T3 PL 1599461T3 PL 04716834 T PL04716834 T PL 04716834T PL 04716834 T PL04716834 T PL 04716834T PL 1599461 T3 PL1599461 T3 PL 1599461T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- activity
- thiolactones
- naaladase
- disease
- Prior art date
Links
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 title abstract 3
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000017497 prostate disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45064803P | 2003-03-03 | 2003-03-03 | |
| EP04716834A EP1599461B1 (en) | 2003-03-03 | 2004-03-03 | THIOLACTONES AS NAALADase INHIBITORS |
| PCT/US2004/006178 WO2004078742A1 (en) | 2003-03-03 | 2004-03-03 | Thiolactones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1599461T3 true PL1599461T3 (pl) | 2009-10-30 |
Family
ID=32962505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04716834T PL1599461T3 (pl) | 2003-03-03 | 2004-03-03 | Tiolaktony jako inhibitory NAALADazy |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7125907B2 (pl) |
| EP (2) | EP1599461B1 (pl) |
| JP (1) | JP4773951B2 (pl) |
| AT (1) | ATE433445T1 (pl) |
| AU (1) | AU2004217969B2 (pl) |
| CA (1) | CA2518234C (pl) |
| CY (1) | CY1109356T1 (pl) |
| DE (1) | DE602004021476D1 (pl) |
| DK (1) | DK1599461T3 (pl) |
| ES (1) | ES2326083T3 (pl) |
| MX (1) | MXPA05009492A (pl) |
| PL (1) | PL1599461T3 (pl) |
| PT (1) | PT1599461E (pl) |
| SI (1) | SI1599461T1 (pl) |
| WO (1) | WO2004078742A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1599461T1 (sl) * | 2003-03-03 | 2009-10-31 | Eisai Corp Of North Amarica | Tiolaktoni kot inhibitorji NAALADaze |
| JP2010516815A (ja) * | 2007-01-31 | 2010-05-20 | ヘラー， アダム | 疼痛の治療のための方法および組成物 |
| US20180236109A1 (en) | 2015-08-20 | 2018-08-23 | Universitat Zu Koln | Pain Tracking by PET-imaging (Pain-TraP) |
| WO2021155167A1 (en) * | 2020-01-31 | 2021-08-05 | The Johns Hopkins University | Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239636A (en) * | 1978-10-23 | 1980-12-16 | Exxon Research & Engineering Co. | Thio-bis-(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions |
| JPH0532659A (ja) * | 1991-08-01 | 1993-02-09 | Tsumura & Co | 糖尿病治療剤 |
| GB9218810D0 (en) | 1992-09-04 | 1992-10-21 | Univ Birmingham | Antiviral pyrimidine nucleosides |
| US6011021A (en) | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| GB9602721D0 (en) | 1996-02-09 | 1996-04-10 | Pharmacia Spa | Biologically active ureido derivatives useful in the treatment of multiple sclerosis |
| US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5804602A (en) * | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US5672592A (en) * | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| RU2218179C2 (ru) * | 1996-06-17 | 2003-12-10 | Гилфорд Фармасьютикалз Инк. | СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы |
| US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US5863536A (en) * | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US5977090A (en) | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US6017903A (en) * | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US6054444A (en) * | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US6384022B1 (en) * | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
| US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US6025345A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| GB9615202D0 (en) | 1996-07-19 | 1996-09-04 | Smithkline Beecham Plc | Pharmaceuticals |
| US5962521A (en) * | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| PL332413A1 (en) * | 1996-09-27 | 1999-09-13 | Guilford Pharm Inc | Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals |
| US5981209A (en) * | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6028216A (en) * | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
| US6121252A (en) * | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
| US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
| US6265609B1 (en) | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
| KR100672965B1 (ko) * | 1998-07-06 | 2007-02-28 | 길포드 파마슈티컬스 인코포레이티드 | 약제학적 화합물로 유용한 나알라다제 억제제 및 그의조성물 |
| US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| AU773915B2 (en) * | 1999-04-28 | 2004-06-10 | Georgetown University | Ligands for metabotropic glutamate receptors |
| US6228888B1 (en) * | 1999-07-01 | 2001-05-08 | Guilford Pharmaceuticals Inc. | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| US6313159B1 (en) * | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
| US6348464B1 (en) * | 1999-11-12 | 2002-02-19 | Guilford Pharmaceuticals, Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
| AU2001265111A1 (en) * | 2000-05-30 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
| CA2410889A1 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating retinal disorders and glaucoma |
| US20020013295A1 (en) * | 2000-05-30 | 2002-01-31 | Slusher Barbara S. | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
| ATE363839T1 (de) * | 2001-01-08 | 2007-06-15 | Pathway Intermediates Ltd | Autoinducer-verbindungen und ihre verwendung |
| FR2819253B1 (fr) * | 2001-01-11 | 2004-12-03 | Servier Lab | Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| MXPA03006467A (es) * | 2001-01-17 | 2004-01-29 | Guilford Pharm Inc | Inibidores de naaladasa a base de tiol. |
| EP1392648A1 (en) * | 2001-05-11 | 2004-03-03 | Guilford Pharmaceuticals Inc. | Hydroxamic acids and acyl hydroxamines as naaladase inhibitors |
| DK1406867T3 (da) * | 2001-05-30 | 2009-04-06 | Eisai Corp North America | Thiolalkylbenzoesyrederivater |
| AU2002364743A1 (en) | 2001-12-28 | 2003-07-24 | Guildford Pharmaceuticals Inc. | Naaladase inhibitors for treating huntington's disease |
| WO2004078180A2 (en) * | 2003-03-03 | 2004-09-16 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating opioid tolerance |
| SI1599461T1 (sl) * | 2003-03-03 | 2009-10-31 | Eisai Corp Of North Amarica | Tiolaktoni kot inhibitorji NAALADaze |
-
2004
- 2004-03-03 SI SI200431195T patent/SI1599461T1/sl unknown
- 2004-03-03 ES ES04716834T patent/ES2326083T3/es not_active Expired - Lifetime
- 2004-03-03 EP EP04716834A patent/EP1599461B1/en not_active Expired - Lifetime
- 2004-03-03 PL PL04716834T patent/PL1599461T3/pl unknown
- 2004-03-03 WO PCT/US2004/006178 patent/WO2004078742A1/en not_active Ceased
- 2004-03-03 AT AT04716834T patent/ATE433445T1/de active
- 2004-03-03 EP EP08013761A patent/EP1988088A1/en not_active Withdrawn
- 2004-03-03 PT PT04716834T patent/PT1599461E/pt unknown
- 2004-03-03 AU AU2004217969A patent/AU2004217969B2/en not_active Ceased
- 2004-03-03 DE DE602004021476T patent/DE602004021476D1/de not_active Expired - Lifetime
- 2004-03-03 DK DK04716834T patent/DK1599461T3/da active
- 2004-03-03 JP JP2006508945A patent/JP4773951B2/ja not_active Expired - Fee Related
- 2004-03-03 CA CA2518234A patent/CA2518234C/en not_active Expired - Fee Related
- 2004-03-03 MX MXPA05009492A patent/MXPA05009492A/es active IP Right Grant
- 2004-03-03 US US10/791,278 patent/US7125907B2/en not_active Expired - Fee Related
-
2006
- 2006-10-02 US US11/537,979 patent/US20070037798A1/en not_active Abandoned
-
2007
- 2007-07-30 US US11/830,737 patent/US7553866B2/en not_active Expired - Fee Related
-
2009
- 2009-05-26 US US12/472,251 patent/US7968593B2/en not_active Expired - Fee Related
- 2009-08-28 CY CY20091100904T patent/CY1109356T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100048667A1 (en) | 2010-02-25 |
| MXPA05009492A (es) | 2005-12-14 |
| ATE433445T1 (de) | 2009-06-15 |
| AU2004217969B2 (en) | 2011-03-03 |
| US7968593B2 (en) | 2011-06-28 |
| EP1599461B1 (en) | 2009-06-10 |
| JP2006519858A (ja) | 2006-08-31 |
| US7125907B2 (en) | 2006-10-24 |
| CA2518234A1 (en) | 2004-09-16 |
| EP1988088A1 (en) | 2008-11-05 |
| US20080004334A1 (en) | 2008-01-03 |
| PT1599461E (pt) | 2009-07-20 |
| DE602004021476D1 (de) | 2009-07-23 |
| US20070037798A1 (en) | 2007-02-15 |
| WO2004078742A1 (en) | 2004-09-16 |
| ES2326083T3 (es) | 2009-09-30 |
| CY1109356T1 (el) | 2014-07-02 |
| DK1599461T3 (da) | 2009-08-17 |
| CA2518234C (en) | 2012-11-13 |
| US20050004203A1 (en) | 2005-01-06 |
| AU2004217969A1 (en) | 2004-09-16 |
| SI1599461T1 (sl) | 2009-10-31 |
| EP1599461A1 (en) | 2005-11-30 |
| JP4773951B2 (ja) | 2011-09-14 |
| US7553866B2 (en) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003057670A3 (en) | Indoles as naaladase inhibitors | |
| WO2002057222A3 (en) | Thiol-based naaladase inhibitors | |
| WO2001092273A3 (en) | Benzenedicarboxylic acid derivatives | |
| CY1108893T1 (el) | Παραγωγα θειοαλκυλ βενζοϊκου οξεος | |
| BR0215429A (pt) | Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente | |
| BR0313299A (pt) | Processos para tratar distúrbios mediados por anidrase carbÈnica | |
| TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
| DE69940951D1 (de) | Nd wachstumshemmende mittel | |
| BR0108175A (pt) | Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais | |
| DE60219614D1 (de) | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| PL346762A1 (en) | Naaladase inhibitors useful as pharmaceutical compounds and compositions | |
| WO2002062777A3 (en) | Amino ceramide-like compounds and therapeutic methods of use | |
| ATE435026T1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
| MXPA03010328A (es) | Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa. | |
| CY1109356T1 (el) | Θειολακτονες ως αναστολεις της νααladασης | |
| WO2004030618A3 (en) | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | |
| DE602004027255D1 (de) | Peptidische Verbindungen und deren Ableitungen für die Behandllung von menschlichen Krankheiten durch Hemmung der Signalübertragung über Wachstumfaktoren | |
| ID29970A (id) | Metode untuk mengobati penyakit neovaskuler okuler | |
| BRPI0408238A (pt) | anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer | |
| WO2005000406A3 (en) | Treatment of amyloid- and epileptogenesis-associated diseases | |
| WO2002086084A3 (en) | Sequence characteristics of bladder cancer | |
| WO2002089848A3 (en) | Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes | |
| BR0308911A (pt) | Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto | |
| WO2004071411A3 (en) | Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620 |